MedWatch

Analyst: Kesimpta sales from Novartis slightly over expectations

Analysts had somewhat underestimated Novartis’ Q1 sales of multiple sclerosis drug Kesimpta. According to an equity analyst at Sydbank, this is an advantage for biotech firm Genmab, which is behind developing the drug and receives royalties from Novartis.

Photo: Joost Melis / Genmab / PR

In the first quarter of fiscal 2022, Genmab has received USD 19.5m from sales of multiple sclerosis drug Kesimpta, which has been licensed to Swiss firm Novartis.

Genmab is behind the active ingredient, ofatumumab, in Novartis’ Kesimpta, and the Danish biotech firm receives 10-percent royalties from Novartis’s sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs